RJA
VXRT

Raymond James & Associates’s Vaxart VXRT Stock Holding History

Raymond James & Associates’s Portfolio VXRT Stock Details VXRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$17K – 4117
2020
Q4 		$17K Buy
+15,000
New +$95.4K ﹤0.01% 3701

Other funds holding VXRT

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James & Associates's VXRT Position: Q3 2024 in Review

Raymond James & Associates reduced its Vaxart (VXRT) stake by 27% in Q3 2024, selling an estimated $3.4K and leaving 12,279 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3968.

Raymond James & Associates first reported a position in VXRT in Q3 2020 and has held it in 17 quarters since. The position peaked at $302K in Q3 2021. 100 funds tracked by Wall St. Rank hold VXRT as of Q3 2024.

  • Raymond James & Associates held 12,279 shares of Vaxart worth $10.4K as of Q3 2024.
  • Raymond James & Associates sold 4,447 Vaxart shares in Q3 2024, an estimated $3.4K.
  • Vaxart made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3968 holding.
  • Raymond James & Associates first reported a position in Vaxart in Q3 2020 and has held it in 17 quarters since.
  • Raymond James & Associates's Vaxart position peaked at $302K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Vaxart as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.